No Data
No Data
Craig-Hallum Sticks to Its Buy Rating for Rezolute (RZLT)
Express News | Rezolute Inc : Maxim Group Raises Target Price to $15 From $12
Ensysce Biosciences ENSC Patent; Rezolute RZLT Offering and Data Monitoring Committee
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
Rezolute Shares Are Trading Higher After the Company Announced the Data Monitoring Committee Has Recommended the Continuation of Its Phase 3 Sunrize Study.
Rezolute's Promising Clinical Developments and Positive Outlook: A Buy Recommendation by Yun Zhong